These mechanistic studies might reveal whether IL-17A-related inflammatory pathways are a cause or consequence of detrimental outcomes in HIV-1 and HIV–tuberculosis co-infection and thus potentially inform novel therapeutic targets. This evidence concerns the gene IL17A and tuberculosis.